Biopharmaceutical Company Announces Results For Guillain-Barré Syndrome
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome.
Disclaimer: The following article provides an in-depth overview of Annexon's announcement regarding the positive topline results from their pivotal Phase 3 trial for ANX005 in Guillain-Barré Syndrome (GBS). This article is intended for informational purposes only and should not be construed as medical advice. For medical guidance…